EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Toxicological and Liver Antioxidant Evaluation of Phillygenin Following Acute and Sub‐Chronic Oral Administration

Jiyu Qian, Kang Zhang, Guowei Xu, Bingbing Meng, Lei Wang, Jianxi Li, Xiaomeng Chai, Jingyan Zhang, Haipeng Feng

Journal of Applied Toxicology · 2026-12 · 46 (12) · 4683-4696

DOI: 10.1002/jat.70224 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Phillygenin (PHI), a bioactive ligand extracted from Forsythia suspensa , has garnered considerable attention due to its potent medicinal properties in antioxidant and antiviral. However, comprehensive toxicological data supporting its safe application remain scarce. In the present study, the oral safety profile of PHI was assessed following the Organization for Economic Cooperation and Development (OECD) guidelines 423 and 407. For acute toxicity assay, a single dose of 5000 mg/kg body weight (BW) of PHI was given orally to KM mice, with clinical observations maintained for 14 days. No treatment‐related mortality or toxic manifestations were observed, indicating an LD 50 exceeding 5000 mg/kg BW. In the 28‐day sub‐chronic toxicity assay, SD male/female mice received PHI at 5000, 15000, and 25,000 mg/kg BW. Across all dose groups, no adverse effects were observed in clinical signs, organ to weight ratio, body weight, food and water consumption, and biochemical parameters. Additionally, histopathological examination revealed normal organ status. To further explore hepatic functional response, antioxidant indices and key drug‐metabolizing enzymes were quantified in rat liver. PHI significantly enhanced hepatic antioxidant capacity, reflected by increased SOD and GSH levels and reduced MDA content. Moreover, PHI markedly suppressed the transcription level and protein expression of PXR and its downstream enzyme CYP3A1, suggesting a modulatory effect on xenobiotic metabolism. Collectively, these findings demonstrate that PHI exhibits a wide margin of oral safety and exerts beneficial regulatory effects on hepatic antioxidant function. This systematic evaluation provides essential evidence supporting the potential use of PHI as a safe antiviral and antioxidant agent in veterinary clinical application.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →